Stockreport

BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart [Seeking Alpha]

Bristol-Myers Squibb Company  (BMY) 
Last bristol-myers squibb company earnings: 2/6 07:05 am Check Earnings Report
US:NYSE Investor Relations: bms.com/investors.html
PDF BNTX's gotistobart delivered a 63.1% 12-month OS rate versus 30.3% for docetaxel, reducing risk of death by 54%. Upcoming pivotal phase 3 PRESERVE-003 data in 2026 an [Read more]